Lv1
38 积分 2021-09-02 加入
Osimertinib as first-line treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting: updated overall survival data (OSI-FACT-OS)
1天前
求助中
Non-small-cell lung cancer
8天前
已完结
Comparing the effectiveness and safety of first-line interventions in patients with advanced epidermal growth factor receptor-mutant non-small cell lung cancer, with particular focus on brain metastatic status: a systematic review and network meta-analysis
2个月前
已完结
Comparing the effectiveness and safety of first-line interventions in patients with advanced epidermal growth factor receptor-mutant non-small cell lung cancer, with particular focus on brain metastatic status: a systematic review and network meta-analysis
2个月前
已完结
Genomic and Immune Landscape Comparison of MET Exon 14 Skipping and MET-Amplified Non-small Cell Lung Cancer
5个月前
已完结
c-MET pathway in human malignancies and its targeting by natural compounds for cancer therapy
6个月前
已完结
Gefitinib vs Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Variant Lung Cancer—Long-Term Results of a Randomized Clinical Trial
6个月前
已完结
Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP)
7个月前
已完结
Overcoming therapy resistance in EGFR-mutant lung cancer
7个月前
已完结
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)
7个月前
已完结
皖公网安备34019202002308
